PART I O verview We were founded on the belief that engineered cells will be one of the most important transformations in medicine over the next several decades. The burden of diseases that can be addressed at their root cause through engineered cells is significant. We view engineered cells as having the potential to be as therapeutically disruptive as biologic drugs to clinical practice, enabling us to repair cells in the body when possible and replace them when needed. We have developed ex vi...
Q2 FY2026 — expected 2026-09-10
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-03 | 2025-12-31 | 0001193125-26-088215 | EDGAR | 143K words |
| 2025-03-17 | 2024-12-31 | 0000950170-25-040254 | EDGAR | — |
| 2024-02-29 | 2023-12-31 | 0000950170-24-023119 | EDGAR | — |
| 2023-03-16 | 2022-12-31 | 0001564590-23-003798 | EDGAR | — |
| 2022-03-16 | 2021-12-31 | 0001564590-22-010539 | EDGAR | — |
| 2021-03-24 | 2020-12-31 | 0001193125-21-092650 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001193125-25-269569 | EDGAR | 91K words |
| 2025-08-11 | 2025-06-30 | 0001770121-25-000010 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0000950170-25-066943 | EDGAR | — |
| 2024-11-08 | 2024-09-30 | 0000950170-24-123730 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0000950170-24-094052 | EDGAR | — |
| 2024-05-08 | 2024-03-31 | 0000950170-24-055727 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0000950170-23-061171 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0000950170-23-038050 | EDGAR | — |
| 2023-05-08 | 2023-03-31 | 0001564590-23-007074 | EDGAR | — |
| 2022-11-02 | 2022-09-30 | 0001564590-22-036375 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001564590-22-028036 | EDGAR | — |
| 2022-05-10 | 2022-03-31 | 0001564590-22-019299 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-03 | 0001193125-26-088203 | EDGAR | 5K words |
| 2026-02-17 | 0001193125-26-053294 | EDGAR | — |
| 2026-01-14 | 0001193125-26-012664 | EDGAR | — |
| 2025-11-06 | 0001193125-25-269522 | EDGAR | — |
| 2025-09-05 | 0001193125-25-196414 | EDGAR | — |
| 2025-08-29 | 0001193125-25-192766 | EDGAR | — |
| 2025-08-11 | 0001770121-25-000009 | EDGAR | — |
| 2025-08-07 | 0001193125-25-175571 | EDGAR | — |
| 2025-08-06 | 0001193125-25-174506 | EDGAR | — |
| 2025-06-23 | 0000950170-25-088752 | EDGAR | — |
94 total filings indexed. 66 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001770121 |
| Ticker | SANA |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.sana.com |
| Listed | 2021-02-04 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report